Cardiac gene therapy: From concept to reality

被引:9
作者
Razmig Garo Kratlian
Roger J. Hajjar
机构
[1] Cardiovascular Research Center, Mount Sinai School of Medicine, Box 1030, New York, NY 10029, OneGustave L. Levy Place
关键词
Adeno-associated virus; Calcium cycling proteins; Gene therapy; Heart failure; Inhibitor; 1; Neutralizing antibodies; Pharmacologic therapy; Phospholamban; Protein phosphatase 1; SERCA2a;
D O I
10.1007/s11897-011-0077-1
中图分类号
学科分类号
摘要
Heart failure is increasing in incidence throughout the world, especially in industrialized countries. Although the current therapeutic modalities have been successful in stabilizing the course of heart failure, morbidity and mortality remain quite high and there remains a great need for innovative breakthroughs that will offer new treatment strategies for patients with advanced forms of the disease. The past few years have witnessed a greater understanding of the molecular underpinnings of the failing heart, paving the way for novel strategies in modulating the cellular environment. As such, gene therapy has recently emerged as a powerful tool offering the promise of a new paradigm for alleviating heart failure. Current gene therapy research for heart failure is focused on exploring potential cellular targets and preclinical and clinical studies are ongoing toward the realization of this goal. Efforts also include the development of sophisticated viral vectors and vector delivery methods for efficient transduction of cardiomyocytes. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码:33 / 39
页数:6
相关论文
共 49 条
  • [1] Roger V.L., Go A.S., Lloyd-Jones D.M., Et al., Heart disease and stroke statistics-2011 update: A report from the American Heart Association, Circulation, 123, 4, (2011)
  • [2] Lloyd-Jones D., Adams R.J., Brown T.M., Et al., Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association, Circulation, 121, 7, pp. 948-954, (2010)
  • [3] Bers D.M., Calcium fluxes involved in control of cardiac myocyte contraction, Circulation Research, 87, 4, pp. 275-281, (2000)
  • [4] Katz A.M., Lorell B.H., Regulation of cardiac contraction and relaxation, Circulation, 102, 20 SUPPL. 4, (2000)
  • [5] Nicolaou P., Rodriguez P., Ren X., Et al., Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury, Circ Res., 104, 8, pp. 1012-1020, (2009)
  • [6] Nicolaou P., Hajjar R.J., Kranias E.G., Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology, J Mol Cell Cardiol., 47, 3, pp. 365-371, (2009)
  • [7] Dhalla N.S., Saini-Chohan H.K., Rodriguez-Leyva D., Et al., Subcellular remodelling may induce cardiac dysfunction in congestive heart failure, Cardiovasc Res., 81, 3, pp. 429-438, (2009)
  • [8] Gwathmey J.K., Copelas L., MacKinnon R., Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure, Circulation Research, 61, 1, pp. 70-76, (1987)
  • [9] Schmidt U., Hajjar R.J., Helm P.A., Kim C.S., Doye A.A., Gwathmey J.K., Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure, Journal of Molecular and Cellular Cardiology, 30, 10, pp. 1929-1937, (1998)
  • [10] Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., Ly H., Kawase Y., Wagner K., Borow K., Jaski B., London B., Greenberg B., Pauly D.F., Patten R., Starling R., Mancini D., Jessup M., Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure, Journal of Cardiac Failure, 14, 5, pp. 355-367, (2008)